Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth Launched Exclusively by LabCorp
LabCorp® (NYSE: LH) today announced the nationwide availability of the PreTRM® test. Developed by Sera Prognostics, Inc., the PreTRM test...
XABLECATH FEATURED IN MEDTECH STRATEGIST AS A STARTUP TO WATCH IN 2018
Salt Lake City, UT – May 11, 2018 – UpStart portfolio company Xablecath offering peripheral vascular interventional tech- nologies appears in the "START-UPS TO WATCH" section of the May edition of MedTech Strategist.
SERA PROGNOSTICS IS NAMED A 2017 SILVER EDISON AWARD WINNER
New York, NY – April 21, 2017 – The Edison Awards, celebrating 30 years of honoring the best in innovation and excellence in the development of new products and services, announced today that Sera Prognostics’ PreTRM Test was voted a Silver Winner for innovation in the “Health and Wellness” category at the April 20th event at The Capitale in New York City.